Brief: FDA Approves Guardant360 CDX As Companion Diagnostic For Eli Lilly
29/09/2025 13:48
Sept 29 (Reuters) - Guardant Health Inc GH.O: FDA APPROVES GUARDANT360® CDX AS COMPANION DIAGNOSTIC FOR ELI LILLY AND COMPANY’S INLURIYO™ (IMLUNESTRANT) FOR TREATMENT OF ESR1-MUTATED ADVANCED BREAST CANCER Source text: ID:nBw8PDYNPa Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsU.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte